Research paperCyclosporin A affects the bioavailability of ginkgolic acids via inhibition of P-gp and BCRP
-
Add time:08/30/2019 Source:sciencedirect.com
Ginkgolic acids (GAs) in natural product Ginkgo biloba L. are the pharmacological active but also toxic components. Two compounds, GA (C15:1) and GA (C17:1) are the most abundant GAs. In this study, several in vitro and in vivo models were applied to investigate transport mechanism of GAs. A rapid and sensitive LC–MS/MS method for the simultaneous determination of GA (C15:1) and GA (C17:1) was applied to analyze the biological specimens. The Papp(AP→BL) values of GA (C15:1) and GA (C17:1) were 1.66–2.13 × 10−6 cm/s and 1.34–1.85 × 10−6 cm/s determined using MDCK and MDCK-MDR1 cell monolayers, respectively. The Papp(BL→AP) were remarkably greater in the MDCK-MDR1 cell line, which were 6.77–11.2 × 10−6 cm/s for GA (C15:1) and 4.73–5.15 × 10−6 cm/s for GA (C17:1). Similar results were obtained in LLC-PK1 and LLC-PK1-BCRP cell monolayers. The net efflux ratio of GA (C15:1) and GA (C17:1) in both cell models was greater than 2 and markedly reduced by the presence of Cyclosporin A (CsA) or GF120918, inhibitors of P-gp and BCRP, suggesting that GAs are P-gp and BCRP substrates. The results from a rat bioavailability study also showed that co-administrating CsA intravenously (20 mg/kg) could significantly increase GA (C15:1) and GA (C17:1) AUC0−t by 1.46-fold and 1.53-fold and brain concentration levels of 1.43-fold and 1.51-fold, respectively, due to the inhibition of P-gp and BCRP efflux transporters by CsA.
We also recommend Trading Suppliers and Manufacturers of Ginkgolic Acid C17:1 (cas 111047-30-4). Pls Click Website Link as below: cas 111047-30-4 suppliers
Prev:Simultaneous quantification and semi-quantification of ginkgolic acids and their metabolites in rat plasma by UHPLC–LTQ–Orbitrap–MS and its application to pharmacokinetics study
Next:Pharmacological inhibition of SUMO-1 with ginkgolic acid alleviates cardiac fibrosis induced by myocardial infarction in mice) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Pharmacological inhibition of SUMO-1 with ginkgolic acid alleviates cardiac fibrosis induced by myocardial infarction in mice08/31/2019
- Simultaneous quantification and semi-quantification of ginkgolic acids and their metabolites in rat plasma by UHPLC–LTQ–Orbitrap–MS and its application to pharmacokinetics study08/29/2019
- Ginkgolic acids and Ginkgo biloba extract inhibit Escherichia coli O157:H7 and Staphylococcus aureus biofilm formation08/28/2019
- An efficient method for the preparative separation and isolation of ginkgolic acids from the sarcotesta of Ginkgo biloba L by pH-zone-refining counter-current chromatography coupled with inner-recycling mode08/27/2019
- Non-specific SIRT inhibition as a mechanism for the cytotoxicity of ginkgolic acids and urushiols08/26/2019
- 1H NMR-based metabolomics study of liver damage induced by ginkgolic acid (15:1) in mice08/25/2019
- Metabolic profile of ginkgo kernel juice fermented with lactic aicd bacteria: A potential way to degrade ginkgolic acids and enrich terpene lactones and phenolics08/24/2019
- The catalytic activity for ginkgolic acid biodegradation, homology modeling and molecular dynamic simulation of salicylic acid decarboxylase08/23/2019
- Thermal stability of ginkgolic acids from Ginkgo biloba and the effects of ginkgol C17:1 on the apoptosis and migration of SMMC7721 cells08/22/2019
-
Health and Chemical more >


